Gaplinc regulates myeloid metabolic pathways in trans in endotoxic shock.

The long noncoding RNA (lncRNA) Gaplinc is a known regulator of the innate immune response; however, the systemic mechanisms governing its influence on survival during endotoxic shock remain incompletely understood. Here, we establish Gaplinc as a dosage-dependent immune and metabolic rheostat. While Gaplinc knockout (KO) mice exhibit elevated baseline immune response genes (IRGs) and resistance to lipopolysaccharide (LPS)-induced shock, we demonstrate that transgenic Gaplinc overexpression prod
The long noncoding RNA (lncRNA) Gaplinc is a known regulator of the innate immune response; however, the systemic mechanisms governing its influence on survival during endotoxic shock remain incompletely understood. Here, we establish Gaplinc as a dosage-dependent immune and metabolic rheostat. While Gaplinc knockout (KO) mice exhibit elevated baseline immune response genes (IRGs) and resistance to lipopolysaccharide (LPS)-induced shock, we demonstrate that transgenic Gaplinc overexpression produces the opposite phenotype: suppressed baseline IRGs, diminished nuclear p65, and hypersensitivity to endotoxemia. Analysis of heterozygous and rescue models reveals that Gaplinc functions in trans and is haploinsufficient, requiring strict transcript dosage to maintain wild-type immune homeostasis. To uncover the mechanistic basis of this survival advantage, we performed RNA Antisense Purification (RAP-MS) and identified the mitochondrial enzyme MCCC1 as a primary Gaplinc binding partner. Loss of Gaplinc drives systemic metabolic reprogramming, characterized by reduced mitochondrial reactive oxygen species and a protective lipidome featuring elevated lysophosphatidylcholines and diminished free fatty acids. Finally, while myeloid-specific conditional KOs confer partial protection against LPS-induced hypothermia, tissue-wide expression mapping and sex-dimorphic clinical chemistries suggest a broader, multisystemic role for the lncRNA. Collectively, these data demonstrate that Gaplinc bridges transcriptomic immune regulation with systemic lipid and metabolic output, dictating survival outcomes in systemic inflammation.




